Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-cohort, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Envofolimab in Combination With BD0801 Injection With/Without Chemotherapy in Patients With Advanced Solid Tumors

X
Trial Profile

An Open Label, Multi-cohort, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Envofolimab in Combination With BD0801 Injection With/Without Chemotherapy in Patients With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 5-fluorouridine (Primary) ; Docetaxel (Primary) ; Envafolimab (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Sevacizumab (Primary)
  • Indications Cholangiocarcinoma; Colorectal cancer; Liver cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Jiangsu Simcere Pharmaceutical
  • Most Recent Events

    • 10 Mar 2024 Status changed from recruiting to discontinued. (The study was terminated due to the sponsor's research and development strategy adjustment.)
    • 24 Oct 2023 Results (As of March 31, 2023, n=40)presented at the 48th European Society for Medical Oncology Congress
    • 24 Oct 2023 Results (As of March 31,2023; n=20) assessing the efficacy and safety of the combination of suvemcitug and envafolimab as second-line or later therapy in patients (pts) with advanced HCC, presented at the 48th European Society for Medical Oncology Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top